Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

New Alliance Capital

Investor type Venture Capital
Founders Liefeng Qu

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 47
Average round size
info
The average size of a deal this fund participated in
$46M
Portfolio companies 37
Rounds per year 3.13
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.21
Exits 3
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Manufacturing
  • Medical
  • Pharmaceutical
Summary

New Alliance Capital is the famous VC, which was founded in 2008. The main department of described VC is located in the Shanghai. The venture was found in Asia in China.

We can highlight the next thriving fund investment areas, such as Medical Device, Enterprise. The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Sight Diagnostics, Wuhan Zebra Express, ShopEx

This New Alliance Capital works on 18 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2018. When the investment is from New Alliance Capital the average startup value is 500 millions - 1 billion dollars. Considering the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations.

The fund was created by Liefeng Qu. We also calculated 3 valuable employees in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the New Alliance Capital, startups are often financed by Sequoia Capital China, Qiming Venture Partners, OurCrowd. The meaningful sponsors for the fund in investment in the same round are Shenzhen Capital Group, Tranquility Capital, Sequoia Capital China. In the next rounds fund is usually obtained by QJY Capital, Tranquility Capital, Steven Esrick.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of New Alliance Capital:
Typical Co-investors
New Alliance Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after New Alliance Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Doral Energy-Tech Ventures Israel, Ramat Gan, Tel Aviv
Exponentially I Mobility India, Maharashtra, Mumbai
Grandbridge -
Green Dot Capital Central, Central Region, Singapore
HAT Sicaf SpA Italy, Lombardia, Milano
IRDI SORIDEC Gestion -
Juhe Touzi Anhui, China, Hefei
Lendingkart Ahmedabad, Gujarat, India
Napier Park Financial Partners New York, New York, United States
Navus Ventures Netherlands, South Holland, The Netherlands
Newton Press Japan, Tokyo
Polish Agency for Enterprise Development Mazowieckie, Poland, Warszawa
Rock Central Detroit, Michigan, United States
Toyota Industries Corp Awaji, Hyogo Prefecture, Japan
U.S. Army Medical Research & Development Command Louisiana, Maryland, United States
Valid S.A Brazil, São Paulo, Sao Paulo
Weingart Foundation California, Los Angeles, United States
Ysios Capital Barcelona, Catalonia, Spain

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

GenScript ProBio

Biopharma
Medical
Pharmaceutical
$220M18 Jan 2023 Nanjing, Jiangsu, China

Core Medical Technology

Manufacturing
Medical
Medical Device
30 Dec 2022 Shenzhen, Guangdong, China

NeuroXess

Health Care
Health Diagnostics
Medical
28 Dec 2022 Huangpu, Shanghai, China

Kactus Biosystems

Biotechnology
Health Care
$29M19 Oct 2022 Shanghai, China

Yuntu Semiconductor

Application Specific Integrated Circuit (ASIC)
Electronics
Manufacturing
Semiconductor
29 Jul 2022 Suzhou, Jiangsu, China

ATAPEX

Manufacturing
Semiconductor
$15M12 Jul 2022 Jiaxing, Zhejiang, China

Lips Semiconductor

Automotive
Electronics
Industrial
Manufacturing
Semiconductor
$6M01 Apr 2022 Wuxi, Anhui, China

NeuroXess

Health Care
Health Diagnostics
Medical
$14M11 Jan 2022 Huangpu, Shanghai, China

Yuntu Semiconductor

Application Specific Integrated Circuit (ASIC)
Electronics
Manufacturing
Semiconductor
$15M31 Dec 2021 Suzhou, Jiangsu, China
News
Lynk Pharmaceuticals Closes $50M Series B Financing

– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.

Tavotek Biotherapeutics Snares $20M in Series A

– Tavotek Biotherapeutics from Lower Gwynedd, Pennsylvania, has raised over $20M in financing in the preceding two months.
YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital.
– Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent New Alliance Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: